Literature DB >> 8506907

Clinical findings in Brown-McLean syndrome.

T W Gothard1, D R Hardten, S S Lane, D J Doughman, J H Krachmer, E J Holland.   

Abstract

The Brown-McLean syndrome is a clinical condition with corneal edema involving the peripheral 2 to 3 mm of the cornea. The edema typically starts inferiorly and progresses circumferentially, but spares the central portion of the cornea. Additionally, the edema is associated with a punctate orange-brown pigmentation on the endothelium underlying the edematous areas. Central cornea guttata is frequently seen. This condition occurs most frequently after intracapsular cataract extraction, but may also occur after extracapsular cataract extraction and phacoemulsification, or pars plana lensectomy and vitrectomy. Surgical complications and multiple intraocular procedures are frequently observed in these patients. Less frequently, the Brown-McLean syndrome can occur in eyes that have not had surgery. We studied the clinical characteristics of 43 affected eyes of 32 patients. New findings included Brown-McLean syndrome occurring in two eyes of a phakic patient with intermittent angle-closure glaucoma. Two eyes developed Brown-McLean syndrome after phacoemulsification and one eye developed peripheral edema after pars plana vitrectomy and lensectomy. Additionally, severe, infectious keratitis occurred after rupture of peripheral bullae in two eyes. Patients with this condition should be examined periodically and educated regarding the early clinical signs of corneal ulceration.

Entities:  

Mesh:

Year:  1993        PMID: 8506907     DOI: 10.1016/s0002-9394(14)73639-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Mitochondrial myopathy presenting with segmental corneal oedema and retrocorneal membrane.

Authors:  Marcus H Colyer; Kraig S Bower; Thomas P Ward; Ahmad A Hidayat; Prem S Subramanian
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

2.  Brown-McLean syndrome.

Authors:  Ka Wai Kam; Vishal Jhanji; Alvin L Young
Journal:  BMJ Case Rep       Date:  2013-10-09

3.  Brown-McLean Syndrome in a Patient with Hallermann-Streiff Syndrome.

Authors:  Masoumeh Mohebbi; Mahla Shadravan; Elias Khalili Pour; Kambiz Ameli; Sajad Badiei
Journal:  Korean J Ophthalmol       Date:  2016-01-21

4.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 5.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

6.  Corona sign: manifestation of peripheral corneal epithelial edema as a possible marker of the progression of corneal endothelial dysfunction.

Authors:  Tomoyuki Inoue; Yuko Hara; Takeshi Kobayashi; Xiaodong Zheng; Takashi Suzuki; Atsushi Shiraishi; Yuichi Ohashi
Journal:  Jpn J Ophthalmol       Date:  2016-07-05       Impact factor: 2.447

7.  Brown-McLean Syndrome in a Pediatric Patient.

Authors:  Abdo Karim Tourkmani; Jaime D Martinez; David Berrones; Brenda Y Juárez-Domínguez; Francisco Beltrán; Anat Galor
Journal:  Case Rep Ophthalmol       Date:  2015-04-24

8.  Brown-McLean syndrome revisited.

Authors:  Samrat Chatterjee; Swapnil M Parchand; Debashish Dash; Deepshikha Agrawal
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

9.  Brown-McLean syndrome: the role of iridodonesis.

Authors:  Yanin Suwan; Chaiwat Teekhasaenee; Kaevalin Lekhanont; Wasu Supakontanasan
Journal:  Clin Ophthalmol       Date:  2016-04-15

10.  Brown-McLean syndrome after phacoemulsification.

Authors:  M H Mallikarjun; V Kavitha; J Rajashekar; B V Roopasree; Ankit Deokar
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.